Archived Medical News Stories

<< Back to Main Archives Index

RSSArchived Drug Trial News Stories - September 2010

Date Title Comments Rating
2010-09-30 NIH awards Polymedix $986,000 to develop defensin mimetic antimicrobial compounds for oral candidiasis 0 None
2010-09-30 Avila commences AVL-292 Phase 1 clinical study for B cell cancers and autoimmune diseases 0 None
2010-09-30 Repligen Corporation completes patient enrollment in RG2417 Phase 2b clinical trial 0 None
2010-09-30 sanofi-aventis announces top-line results from lixisenatide Phase III GETGOAL-L-ASIA trial for Type-2 Diabetes 0 None
2010-09-30 Teva Pharmaceuticals, OncoGenex initiate SYNERGY Phase 3 trial to evaluate custirsen 0 None
2010-09-30 AVEO regains global rights for development, commercialization of AV-299 anti-HGF antibody candidate 0 None
2010-09-30 FDA grants Type B meeting to review Phase III pivotal efficacy protocols for Androxal 0 None
2010-09-30 NIH awards $3.1 million to further fund Inovio's universal SynCon flu vaccine development 0 None
2010-09-30 Circassia announces advancement in T-cell allergy vaccines development 0 None
2010-09-30 ThromboGenics enters 10-year supply agreement with MSD Biologics for microplasmin 0 None
2010-09-30 Zyclara 3.75% more effective than cryotherapy alone in treatment of Actinic Keratoses: Study 0 None
2010-09-30 Santarus, Cosmo announce positive results from budesonide MMX Phase III study in ulcerative colitis 0 None
2010-09-30 ACT updates myoblast program for heart failure treatment 0 5
2010-09-30 Duke receives approval to initiate NPC-1C Phase I trial for advanced pancreatic and colorectal cancer 0 None
2010-09-30 Alnylam Pharmaceuticals publishes ALN-RSV01 Phase IIa study results 0 None
2010-09-30 Memantine enhances language and communication skills in patients with Alzheimer's disease 0 None
2010-09-29 NEUROKIN accentuates its leadership in the treatment of acute neurological diseases 0 None
2010-09-29 Unique genetic markers point to patient response to SCV-07 treatment 0 None
2010-09-29 Medivation and Astellas commence MDV3100 second Phase 3 clinical trial in advanced prostate cancer 0 5
2010-09-29 Keryx commences Zerenex Phase 3 study for hyperphosphatemia in patients with ESRD on dialysis 0 None
2010-09-29 Rigel earns $25M milestone payment from Astrazeneca for clinical development of fostamatinib 0 None
2010-09-29 Pulmokine receives NIH SBIR grants to develop novel treatments for PAH 0 None
2010-09-29 XOMA completes patient enrollment in XOMA 052 Phase 2a trial 0 None
2010-09-29 NIH trial selects Inovio's PENNVAX-G DNA vaccine candidate to evaluate HIV-1 prevalent 0 None
2010-09-29 ZymoGenetics announces positive survival data from IL-21 Phase 2a clinical trial 0 None
2010-09-29 Synosia's SYN-118 HPPD inhibitor beneficial for Parkinson's patients: Study 0 None
2010-09-29 Study finds broader statin use as a cost-effective way to prevent heart attack and stroke 0 None
2010-09-29 Blood journal publishes GMI-1070 pre-clinical data in sickle cell disease model 0 None
2010-09-29 Tamir's compounds perform better than Ganciclovir for Cytomegalovirus disease: Study 0 None
2010-09-29 Combination therapy reduces radiographic evidence of joint destruction in rheumatoid arthritis: Study 0 None
2010-09-29 XenoPort to present XP21279 clinical trial data at World Parkinson Congress meeting 0 None
2010-09-29 Further trials needed to determine clinical application of Abatacept in SLE 0 None
2010-09-29 RV262 Phase I study launched to evaluate DNA prime/MVA vector boost vaccine regimen for HIV 0 None
2010-09-29 HUYA, Quintiles announce agreement to develop HBI-8000 cancer drug 0 None
2010-09-29 NCI awards A&G $1.2M Phase II SBIR grant for development of breast cancer drug candidate 0 None
2010-09-28 PolyMedix begins PMX-30063 Phase 2 clinical trial for bacterial infections 0 None
2010-09-28 Galapagos initiates phase II clinical study of GLPG0259 drug in RA patients 0 None
2010-09-28 GenMark’s eSensor technology selected for Warfarin clinical study 0 5
2010-09-28 PGIC analysis indicates tapentadol ER tablets provide significant improvement in pain intensity 0 None
2010-09-28 Onconova Therapeutics to present Ex-RAD radioprotectant data at RRS Annual Meeting 0 None
2010-09-28 Pfizer ceases SUN 1120 Phase 3 trial of SUTENT in men with CRPC 0 None
2010-09-28 Rockland receives Phase I SBIR grant to develop assay for monitoring Akt pathway activity 0 None
2010-09-27 KAI Pharmaceuticals enrolls patients in Phase 1b study of KAI-4169 for treatment of SHPT 0 None
2010-09-27 Chelsea Therapeutics initiates CH-4051 Phase II trial in rheumatoid arthritis patients 0 None
2010-09-27 REMURA Phase 2 clinical study results highlighted at Tear Film & Ocular Surface conference 0 None
2010-09-27 S*BIO initiates SB939 Phase 2 clinical trial for metastatic prostate cancer 0 None
2010-09-27 MediciNova receives FDA approval to proceed with initial trial of ibudilast 0 None
2010-09-27 Takeda announces SGN-35 ADC trial results in Hodgkin lymphoma patients 0 None
2010-09-27 OncoGenex initiates OGX-427 Phase 2 trial for metastatic prostate cancer 0 None
2010-09-27 Clinical Data announces Stedivaze agonist data at ASNC2010 meeting 0 None
2010-09-27 Astellas Pharma announces Phase IV study results of Lexiscan injection at ASNC session 0 None
2010-09-24 Genta commences new tesetaxel Phase 2 clinical trial in advanced bladder cancer 0 None
2010-09-24 Enobia announces positive results from ENB-0040 Phase II juvenile clinical trial for hypophosphatasia 1 None
2010-09-24 Results of Argos' Arcelis Phase 2 study for RCC accepted for presentation at International Kidney Cancer Symposium 0 None
2010-09-24 Yaupon reports positive results from mechlorethamine gel study for early-stage cutaneous T-cell lymphoma 0 4
2010-09-24 Cylene commences CX-4945 Phase I trial in multiple myeloma 0 None
2010-09-24 Phase 3 clinical study demonstrates efficacy of metformin therapy in type 2 diabetes 0 None
2010-09-24 Biothera receives SBIR award to evaluate therapeutic potential of Imprime PGG drug in pancreatic cancer 0 5
2010-09-23 Tolerx presents otelixizumab preclinical research at 46th EASD 0 None
2010-09-23 FDA grants ZIOPHARM's darinaparsin Orphan Drug Designation for peripheral T-cell Lymphoma treatment 0 None
2010-09-23 Linagliptin clinical trial data shows positive result for type 2 diabetes treatment 0 3
2010-09-23 Athersys presents MultiStem phase I study results at TCT Conference 0 None
2010-09-23 Vaxonco initiates Phase I clinical trial of novel DNA-based polyepitope vaccine against malaria 0 5
2010-09-23 Phase II study: Fostamatinib improves outcomes in RA patients 0 4.3
2010-09-23 Biogen Idec concurs with FDA on safety monitoring for Gilenya through REMS 0 5
2010-09-23 DSMB authorizes Oxygen Biotherapeutics' next cohort of Oxycyte emulsion study in severe non-penetrating TBI 0 None
2010-09-23 Infinity Pharmaceuticals to present IPI-926 inhibitor Phase 1 data at ESMO Congress 0 5
2010-09-23 Weight-based taribavirin reduces anemia, increases sustained virologic response 0 None
2010-09-23 Intarcia Therapeutics presents ITCA 650 phase 2 study results for type 2 diabetes 0 None
2010-09-22 Boehringer Ingelheim to present linagliptin Phase III data at 46th EASD 0 None
2010-09-22 Titan completes enrollment in Probuphine Phase 3 study for opioid addiction 0 None
2010-09-22 Santaris Pharma paves way to conduct clinical trial of miravirsen in patients with HVC 0 5
2010-09-22 Results of custirsen Phase 2 trial for advanced prostate cancer published in Journal of Clinical Oncology 0 None
2010-09-22 Phase I/II DIGNITY trial abstract of ThermoDox accepted for poster session at 2010 Breast Cancer Symposium 0 None
2010-09-22 Progenics completes methylnaltrexone bromide subcutaneous injection phase 3 study in patients with OIC 0 None
2010-09-22 FDA guides Apricus Bio on RayVa's approvability for Raynaud's syndrome secondary to scleroderma 0 None
2010-09-22 Aeras and Crucell commence Phase II study of TB vaccine candidate in infants 0 5
2010-09-22 Novartis' SOM230 reduces cortisol levels in Cushing's disease patients 1 5
2010-09-21 ChemoCentryx presents CCX140 clinical data at EASD 0 None
2010-09-21 NIDA awards 5-year, $3.7M research grant for development of drug to treat cocaine addiction 0 None
2010-09-21 VIVUS announces QNEXA study results for obesity treatment 1 None
2010-09-21 Cytheris commences enrollment in CYT107 recombinant human Interleukin-7 clinical trial for HIV 0 None
2010-09-21 ImmunoGen commences clinical testing with SAR566658 anticancer compound 0 None
2010-09-21 Annals of Internal Medicine publishes GRACE study data on HIV therapy 0 None
2010-09-21 ProtAffin presents impressive efficacy data for PA401 in COPD 0 None
2010-09-21 Inovio Pharmaceuticals completes enrollment for PENNVAX-B vaccine Phase I clinical study 0 None
2010-09-21 Multinational study demonstrates positive effects of laquinimod in patients with RRMS 0 None
2010-09-21 Lixisenatide experimental diabetes drug shows potential in trial 0 None
2010-09-20 Dengue fever vaccine in the pipeline 0 5
2010-09-20 Seven abstracts on Lantheus' PET imaging candidates to be presented at ASNC2010 0 None
2010-09-20 Celldex commences CDX-011 Phase 2b trial in advanced breast cancer patients expressing GPNMB 0 5
2010-09-20 Micromet initiates MT103 phase 2 trial in adult ALL patients 0 3
2010-09-20 Dapagliflozin added to glimepiride therapy reduces HbA1c in adult type 2 diabetes patients 0 None
2010-09-20 Sanofi-aventis releases Lantus(R) study results for type 2 diabetes 0 None
2010-09-20 Phase III trial results of lixisenatide for type 2 diabetes presented at 46th EASD 0 None
2010-09-20 Myrexis releases MPC-9528 cancer metabolism inhibitor preclinical study results 0 None
2010-09-20 Chelsea Therapeutics' Phase III NORTHERA Study 301 meets primary endpoint 0 None
2010-09-18 ONS trial results show promise for treating medically refractory chronic migraines: ONSTIM study 0 None
2010-09-18 Emisphere’s SNAC drug successful in reducing food intake; increasing satiety 0 None
2010-09-18 Minocycline plus N-acetylcysteine may help treat TBI 0 None
2010-09-18 Boehringer Ingelheim commences afatinib Phase III clinical trial in advanced breast cancer 0 None
2010-09-17 Aradigm to present Phase 1 studies of inhaled liposomal ciprofloxacin at 2010 ERS Congress 0 4
2010-09-17 Transition stops TT-223 gastrin analogue combination clinical study in type 2 diabetes 0 None
2010-09-17 Scott & White Healthcare recruits patients for Phase III lung cancer trial 0 2
2010-09-17 LigoCyte to enroll 98 subjects in first clinical trial for bivalent IM norovirus vaccine 0 None
2010-09-17 FDA grants AGTC $1M for Phase II human clinical trial in alpha-1 antitrypsin deficiency 0 None
2010-09-16 ISTA Pharmaceuticals initiates REMURA Phase 3 clinical program for dry eye disease 0 None
2010-09-16 BioCryst Pharmaceuticals announces BCX4208 compound results for treating gout 0 None
2010-09-16 Incyte Corporation publishes clinical trial data of INCB18424 drug for myelofibrosis treatment 0 4
2010-09-16 Chimerix presents promising clinical data for CMX001 in late-breaker poster session at 50th ICAAC 0 None
2010-09-16 ViroPharma presents Phase 1 study data of VP20621 at ICAAC 2010 0 None
2010-09-16 Relypsa announces positive results from Phase 2 clinical trial of RLY5016 0 None
2010-09-16 Spirogen, Celtic Therapeutics announces initiation of Phase II ovarian cancer trial with SG2000 0 None
2010-09-15 BioCryst reports results from forodesine studies for CTCL and CLL 0 None
2010-09-15 Abstract on ACH-1625 accepted as late breaking poster presentation at The Liver Meeting 2010 0 None
2010-09-15 Phase II clinical trial shows GTx-758 reduces serum free testosterone 0 None
2010-09-15 COTI selected for Canadian life sciences partnering mission 0 None
2010-09-15 ADVENTRX announces Exelbine 12-month stability test results 0 None
2010-09-15 AVANIR's AVP-923 Phase III STAR trial results published in 'Annals of Neurology' website 0 None
2010-09-15 ITS commences treatment in synthetic universal influenza vaccine Phase I trial 0 None
2010-09-15 AMRI selects compound for advanced preclinical testing in treatment of IBS 0 None
2010-09-15 Harbor BioSciences releases Apoptone clinical trial data for castration resistant prostate cancer 0 None
2010-09-15 Optimer Pharmaceuticals to present fidaxomicin Phase 3 clinical trial data at ICAAC Conference 0 None
2010-09-15 Neurocrine Biosciences announces GSK561679 antagonist's efficacy in major depressive disorder 0 None
2010-09-15 RAB-1 monoclonal antibody study shows positive result for rabies 0 None
2010-09-15 FDA grants Arcion's ARC-4558 Fast Track designation for pain involved in Painful Diabetic Neuropathy 0 None
2010-09-15 PLX-PAD therapy improves quality of life in CLI patients 0 None
2010-09-15 Wintherix announces WX04554 molecule can cause bone healing 0 None
2010-09-15 Provectus completes enrollment in first cohort of PV-10 Phase 1 trial for liver cancer 0 5
2010-09-15 Atox Bio doses first subject in AB103 Phase 1 study for severe bacterial infections and sepsis 0 None
2010-09-14 Data from Phase II trial of zanolimumab in PTCL published in British Journal of Haematology 0 None
2010-09-14 Gentium announces defibrotide presentations at 33rd World Congress of International Society of Hematology 0 None
2010-09-14 Enrollment in Derma Sciences DSC127 Phase 2 trial in diabetic foot ulcer healing to conclude September end 0 None
2010-09-14 VBL Therapeutics' VB-201 candidate delays onset of EAE, shows potential for MS, CNS treatment 0 None
2010-09-14 TransPharma Medical completes ViaDerm-GLP1 agonist Phase 1a trial for type II diabetes 0 None
2010-09-14 Icagen suspends further enrollment in ICA-105665 study 0 None
2010-09-14 AACR, EmergingMed collaborate to connect cancer patients with clinical trials in connection to SU2C broadcast 0 None
2010-09-14 OSUCCC-James researchers identify experimental agent that targets chronic lymphocytic leukemia 0 None
2010-09-14 Switching ACS patients to Effient therapy reduces Maximum Platelet Aggregation 0 2.5
2010-09-14 Ironwood, Forest Laboratories announce positive results for linaclotide Phase 3 clinical trials in IBS-C patients 0 5
2010-09-14 Capstone Therapeutics reaches overall progress in AZX100 Phase 2a clinical trials for keloid scarring 0 None
2010-09-13 High dose peretinoin reduces recurrence of HCC after surgical resection or ablation in HCV positive patients 0 None
2010-09-13 Study finds antibiotic safe for treatment of stroke and good companion therapy for tPA 0 None
2010-09-13 Provectus's PV-10 Phase 2 data to be presented at 7th International Melanoma Research Congress 0 None
2010-09-13 North Mississippi IRB approves CEL-SCI's Multikine Phase III clinical trial for head and neck cancer 0 None
2010-09-13 Ticagrelor exhibits potential for prevention of heart attacks 0 None
2010-09-13 Synta expands STA-9090 Phase 2 clinical trial in NSCLC 0 None
2010-09-13 Jennerex reports positive interim data from trial of JX-594 and sorafenib for liver cancer 0 5
2010-09-13 Pro-Pharmaceuticals engages Numoda Corporation to optimize DAVANAT Phase III clinical trial 0 None
2010-09-13 Incyte Corporation enters SPA agreement with FDA for INCB18424 inhibitor 0 None
2010-09-13 ARIAD commences ponatinib Phase 2 clinical trial in Ph+ ALL and chronic myeloid leukemia 0 None
2010-09-13 XenoPort intends to initiate Phase 3 XP19986 trial for multiple sclerosis 0 None
2010-09-13 Vical's TransVax CMV vaccine achieves key endpoints in Phase 2 trial in immunocompromised HCT recipients 0 None
2010-09-13 Cyclacel reaches SPA agreement with FDA for sapacitabine Phase 3 trial in AML 0 None
2010-09-13 Seattle Genetics' lintuzumab phase IIb clinical trial for AML does not meet primary endpoint 0 None
2010-09-13 Diamyd Medical reports potential results on NP2 Phase I clinical trial for chronic pain 0 None
2010-09-13 Inovio Pharmaceuticals achieves promising results in VGX-3100 Phase I study 0 None
2010-09-13 Genmab announces Phase II ofatumumab study results in RRMS patients 0 None
2010-09-10 Resverlogix announces key changes to Phase 2 ASSURE trial 0 None
2010-09-10 Bioniche reduces net loss per share from $0.15 in fiscal 2009 to $0.02 in fiscal 2010 0 None
2010-09-10 Ortho Biotech unblinded abiraterone acetate Phase 3 study for prostate cancer patients 0 None
2010-09-10 Purdue Pharma to present Butrans Transdermal System CIII clinical program data at PAINWeek 2010 0 None
2010-09-10 FerroKin BioSciences initiates international Phase 2 study of FBS0701 0 None
2010-09-10 Allos Therapeutics to present FOLOTYN trial results at ESMO Congress 0 None
2010-09-09 Seaside reports positive data from STX209 Phase 2 study in ASD 2 None
2010-09-09 Acceleron Pharma and Shire announce joint development of ACE-031 for DMD 0 None
2010-09-09 DARA BioSciences presents KRN5500 study results at World Congress on Pain 0 None
2010-09-09 Aflibercept Phase 3 VELOUR clinical trial for mCRC to continue to completion 0 None
2010-09-09 Researchers find minocycline antibiotics effective for fragile X syndrome 0 3
2010-09-09 NovaBay Pharmaceuticals to deliver new data on Aganocide compounds at ICAAC Conference 0 None
2010-09-09 Insulin may reduce life-threatening bacterial infections in intensive care patients 0 None
2010-09-09 Team of scientists issues HIV vaccine strategy 0 None
2010-09-09 Tetraphase announces 13 data presentations on TP-434 broad spectrum antibiotic at ICAAC 2010 0 None
2010-09-09 Hemispherx Biopharma to present clinical data on XMRV retrovirus at International Workshop 0 None
2010-09-09 ImmunoCellular Therapeutics announces long-term data from ICT-107 Phase I clinical trial for GBM 0 None
2010-09-09 EDAP reports clinical outcomes of Ablatherm-HIFU treatment in prostate cancer patients 0 3
2010-09-09 Switching from protease inhibitors to Nevirapine brings superior results for some HIV-infected children 0 None
2010-09-09 GSK, Genmab commence ofatumumab Phase III study in rituximab refractory patients with indolent B-NHL 0 None
2010-09-09 Cylene Pharmaceuticals to report recent developments of CX-4945 inhibitor at CK2 International Conference 0 None
2010-09-09 GE Healthcare's flutemetamol phase 2 study results published in 'Annals of Neurology' 0 None
2010-09-08 Progenics commences Phase 3 trial of oral methylnaltrexone for opioid-induced constipation 0 None
2010-09-08 MAP Pharmaceuticals completes 12 months of treatment in LEVADEX open-label safety trial 0 None
2010-09-08 MAP Pharmaceuticals reports results from PD trial that compares effects of LEVADEX, IV DHE 0 None
2010-09-08 Positive results from YM BioSciences' CYT997 Phase I study for vascular disruption in tumors 0 None
2010-09-08 Emergent BioSolutions initiates Phase I clinical trial for anthrax monoclonal antibody therapeutic 0 None
2010-09-08 Trius Therapeutics announces presentations from drug development programs at 50th ICAAC 0 None
2010-09-08 PLX4032 trial shows high degree of selectivity to achieve tumor shrinkage 0 None
2010-09-08 N30 Pharmaceuticals commences dosing in N6022 GSNOR trial for asthma, COPD and IBD 0 None
2010-09-08 Phase 3 REALIZE study shows milestone in treatment development for hepatitis C 0 4
2010-09-08 Gemcitabine does not improve survival compared with fluorouracil plus folinic acid in resected pancreatic cancer 0 None
2010-09-08 Octapharma announces new study of IVIG in chronic inflammatory demyelinating polyradiculoneuropathy 0 None
2010-09-08 Onyx enters commercialization agreement with Ono for carfilzomib and ONX 0912 development program 0 None
2010-09-08 Jennerex, Transgene enter partnership to develop JX-594 product for tumor treatment 0 None
2010-09-08 ESPAC-3 trial shows promising results to prevent pancreatic cancer 0 None
2010-09-08 Can-Fite BioPharma opens IND with US-FDA for CF101 Phase 3 study in Dry Eye Syndrome 0 None
2010-09-07 Methylphenidate facilitates recovery from drug addiction 0 None
2010-09-07 Rexahn submits Phase IIb protocol to FDA for study of Serdaxin for major depressive disorder 0 None
2010-09-07 CytRx commences PROACT Phase 2 clinical trial of bafetinib for advanced prostate cancer 0 None
2010-09-07 Promedior initiates PRM-151 Phase 2a clinical study in prevention of scarring post glaucoma filtration surgery 0 None
2010-09-07 Positive immune responses elicited from Scancell's DNA vaccine in combination with ImmuneRegen's Homspera 0 None
2010-09-07 TenX Biopharma recommences enrollment in suspended Phase III trial for cutaneous T-cell lymphoma 0 None
2010-09-07 Hallucinogen psilocybin safe for administration in patients with advanced-stage cancer and anxiety: Study 0 None
2010-09-07 Axelar AB publishes first AXL1717 data on phase I/II cancer study 0 None
2010-09-06 Microplasmin MIVI-TRUST Phase III program's positive pooled results presented at EURETINA 0 None
2010-09-04 AVAC calls for economic and political support for CAPRISA 004 microbicide trial's critical follow-up studies 0 None
2010-09-03 Researchers complete INX-189 clinical trials for Hepatitis C virus 0 5
2010-09-03 ImmunoCellular Therapeutics updates accomplishments in Letter to Shareholders 0 None
2010-09-03 Data from ESC confirms reduction in adverse events with CYPHER Stent 0 None
2010-09-03 GOG to conduct Phase II trial on primary peritoneal cancer 0 None
2010-09-03 Gilead Sciences seeks MAA in Europe for fixed-dose combination of Truvada and TMC278 for HIV-1 infection 0 None
2010-09-03 Iroko Cardio International Sàrl announces data on HDB dosing of tirofiban, abciximab in interventional cardiology 0 None
2010-09-03 Seattle Genetics achieves milestone on Agensys' initiation of AGS-16M8F ADC phase I trial for cancer 0 None
2010-09-03 Santhera, Ipsen partner to develop and commercialize fipamezole outside North America and Japan 0 None
2010-09-02 Transdel Pharmaceuticals presents Ketotransdel Phase 3 data at 13th World Pain Congress 0 None
2010-09-02 Halozyme initiates Ultrafast Insulin combination Phase 2 studies with rHuPH20 0 None
2010-09-02 Lytix Biopharma granted Hungarian approval for Lytixar Phase IIa clinical trial in Gram positive skin infections 0 None
2010-09-02 First Phase I/II clinical trial to test MK-0752 in patients with advanced pancreatic cancer 0 None
2010-09-02 Mipomersen Phase 3 trial in heFH meets primary, secondary and tertiary endpoints 0 None
2010-09-02 Inhibitex completes INX-189 Phase1a trial for HCV 0 None
2010-09-02 ThromboGenics second microplasmin Phase III trial for non-surgical treatment of VMA meets primary endpoint 0 5
2010-09-02 Estradiol prevents vascular permeability following hemorrhagic shock: Study 0 None
2010-09-02 Agensys commences AGS-16M8F ADC Phase I clinical trial for renal cancer 0 None
2010-09-02 Sangart reports positive MP4OX Phase IIa study data in severely injured trauma patients with hemorrhagic shock 0 None

Total

223 posts
5 comments
40 raters